Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high-growth tech stocks that can capitalize on such robust earnings growth potential becomes essential for investors seeking opportunities in a dynamic market environment.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 24.13% | 24.28% | ★★★★★★ |
Ardelyx | 22.86% | 54.70% | ★★★★★★ |
AVITA Medical | 33.33% | 51.81% | ★★★★★★ |
Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
AsiaFIN Holdings | 51.75% | 82.69% | ★★★★★★ |
Alnylam Pharmaceuticals | 21.39% | 56.40% | ★★★★★★ |
TG Therapeutics | 30.33% | 44.07% | ★★★★★★ |
Clene | 61.16% | 59.11% | ★★★★★★ |
Blueprint Medicines | 22.61% | 55.18% | ★★★★★★ |
Travere Therapeutics | 29.54% | 61.86% | ★★★★★★ |
Click here to see the full list of 226 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare and orphan diseases, with a market cap of $1.98 billion.
Operations: Mirum Pharmaceuticals focuses on developing and commercializing therapies for rare and orphan diseases, generating $307.03 million in revenue from its pharmaceuticals segment.
Mirum Pharmaceuticals, despite its current unprofitability, is navigating a promising trajectory with expected revenue growth at 23.7% annually, outpacing the broader US market's 9%. This growth is underpinned by robust forecasts that see the company turning profitable within three years—a notable achievement given the industry's competitive intensity. Recent guidance for 2025 projects net product sales reaching up to $435 million, reflecting confidence in sustained demand for their biotechnological innovations. Additionally, Mirum's active participation in key medical conferences underscores its commitment to advancing liver disease treatment, enhancing its visibility and credibility within the biotech sector.
Examine Mirum Pharmaceuticals' past performance report to understand how it has performed in the past.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Enfusion, Inc. offers software-as-a-service solutions tailored for the investment management industry across various regions including the United States, Europe, the Middle East, Africa, and Asia Pacific, with a market capitalization of approximately $1.39 billion.
Operations: Enfusion generates revenue primarily through its online financial information provider services, amounting to $195.16 million. The company operates within the software-as-a-service sector for investment management across multiple global regions.
Enfusion, currently navigating a significant merger with Clearwater Analytics valued at $2.6 billion, showcases a strategic move to enhance its market position and financial robustness. This transaction follows Enfusion's inclusion in the S&P Software & Services Select Industry Index, reflecting its growing industry recognition. Despite a challenging past year with earnings down by 55.5%, Enfusion's commitment to innovation is evident in its R&D spending which remains robust, underpinning future growth prospects in the competitive software sector. The company's recent performance at key technology conferences further solidifies its stature as an influential player in tech circles, poised for recovery and growth post-merger.
Learn about Enfusion's historical performance.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Motorola Solutions, Inc. offers public safety and enterprise security solutions across the United States, the United Kingdom, Canada, and other international markets with a market capitalization of $76.08 billion.
Operations: Motorola Solutions generates revenue through two primary segments: Products and Systems Integration, which contributes $6.82 billion, and Software and Services, contributing $3.83 billion. The company focuses on providing solutions for public safety and enterprise security across various international markets.
Motorola Solutions is carving out a niche in the high-growth tech sector with its latest innovations and strategic contracts. The recent unveiling of the V200 body camera highlights its focus on enhancing safety for frontline workers, a move that not only broadens its product portfolio but also addresses significant market needs in security technology. Additionally, securing a $160 million contract to manage Norway's critical communications network underscores its capability in delivering complex, large-scale solutions essential for public safety. These developments complement an impressive financial performance with third-quarter revenue rising to $2.79 billion from $2.56 billion year-over-year and net income increasing to $562 million from $464 million, reflecting a robust operational execution that aligns well with future growth trajectories in both product innovation and market expansion strategies.
Assess Motorola Solutions' past performance with our detailed historical performance reports.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGM:MIRM NYSE:ENFN and NYSE:MSI.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。